Emerging Biomarker Research Aims to Expand Autism Identification Options

Researchers are exploring new approaches to help recognize autism traits in young children, from analyzing eye movement patterns to examining gut bacteria. These potential biomarkers—measurable biological or behavioral characteristics that may correlate with autism—could one day expand identification options beyond current diagnostic evaluations. However, most remain in research phases, and their applicability across different autistic individuals remains unclear.

Defining Biomarkers

Biomarkers are objective indicators that can be measured consistently, such as particular gaze patterns when viewing social scenes or microbial profiles in stool samples. Unlike diagnostic interviews that assess broad developmental patterns, biomarkers aim to provide specific, measurable signals that may correlate with autism traits.

A 2024 JAMA Network Open study found it could eventually help pediatricians identify children who might benefit from further evaluation.

Microbial Research in Early Stages

A 2026 study in Nature reported distinct gut bacteria patterns in some autistic children, though the research requires replication and the findings may only apply to certain subgroups. Researchers at the Chinese University of Hong Kong are conducting a pilot study of an AI-powered stool analysis tool with just 200 participants—far from clinical implementation. As noted in Frontiers in Psychiatry, such biological markers require years of additional study to determine their reliability and appropriateness for diverse populations.

Eye-Tracking Shows Promise But Remains Investigational

Eye-tracking technology, which measures where children focus their gaze when viewing social interactions, has shown potential in research settings. A 2024 JAMA Network Open study found it could eventually help pediatricians identify children who might benefit from further evaluation. However, as Contemporary Pediatrics notes, these tools remain under study and aren't yet approved for routine clinical use.

Why Earlier Recognition Matters

Research suggests that connecting children with supportive resources aligned with their needs—such as communication supports or sensory accommodations—can improve quality of life. A 2025 review in PMC emphasizes that supportive environments, not early identification alone, drive positive outcomes. However, many families face barriers accessing evaluations, particularly in rural areas, non-English-speaking communities, and under-resourced healthcare systems.

Commercial Tests Outpace Evidence

Some companies have begun marketing tests like ClearStrand-ASD in Japan despite lacking independent validation. Experts universally caution against relying on such commercially available tests, as their accuracy and appropriateness for individual children remain unproven.

Looking Ahead

As a 2024 ScienceDirect review notes, autism's diversity means no single biomarker will likely suit all individuals. The goal is developing multiple validated tools that clinicians can tailor to each child's needs. For now, comprehensive evaluations by qualified professionals remain the gold standard for identification.